Business Context and Reporting Period
Company: Ocular Therapeutix, Inc. (OCUL)
Filing Type: Form 8-K (Current Report)
Date of Report: August 7, 2024
Reporting Period: Second Quarter ended June 30, 2024
Context: This filing serves to announce the financial results for the quarter ended June 30, 2024. The detailed results are contained in a press release furnished as Exhibit 99.1 and incorporated by reference.
Key Financial Metrics
The provided text is a cover page and index for the Form 8-K. It references the existence of financial results but does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These figures are located in the attached Exhibit 99.1 (Press Release), which is not included in the input text.
Material Changes
The filing text does not provide specific details on material changes versus the prior comparable period. It only confirms that results for the quarter ended June 30, 2024, have been announced.
Guidance, Outlook, and Risks
Management Commentary: The filing indicates that management has released financial results via a press release (Exhibit 99.1), but the text of that commentary is not present in this document.
Legal Disclaimer: The information in this 8-K, including the referenced press release, is furnished to comply with Item 2.02 and is not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it subject to the liabilities of that section, except as expressly set forth by specific reference.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 7, 2024) for actual revenue, net loss, and cash position figures.
- Verify the specific details of the "Results of Operations" referenced in Item 2.02, as they are not detailed in the cover page.
- Confirm the company's status as an emerging growth company (indicated by a check mark in the filing) and any associated accounting standard elections.
- Check the Nasdaq Global Market listing status for Common Stock (Symbol: OCUL).